A new analysis, designed to shed light on the benefits of SGLT2 inhibition in patients who have heart failure with preserved ejection fraction (HFpEF), shows that dapagliflozin (Farxiga; AstraZeneca) ...
Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback